TransMedics Group, Inc. ( TMDX ) reported strong YoY growth in the seasonally weak third quarter. In dollar terms, YoY growth was soft, though, highlighting how the liver transplant market in the United States is maturing. TransMedics expects its next-genRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identif ...

TransMedics Group, Inc. ( TMDX ) reported strong YoY growth in the seasonally weak third quarter. In dollar terms, YoY growth was soft, though, highlighting how the liver transplant market in the United States is maturing. TransMedics expects its next-genRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identif ...

Key Takeaways TMDX's Q3 EPS jumped 450% year over year, beating estimates by 78.4%.TMDX's revenue rose 32.2% to $143.8M, led by OCS demand and logistics expansion.TMDX's operating margin expanded to 16.2% as product and service growth accelerated.TransMedics Group, Inc. (TMDX) delivered earnings per share (EPS) of 66 cents in the third quarter of 2025, which surged 450% year over year. The figure surpassed the Zacks Consensus Estimate by 78.4%.TMDX’s Revenues in DetailTransMedics registered revenues of $143 ...

I aim to invest in companies with perfect qualitative attributes, buy them at an attractive price based on fundamentals, and hold them forever. I hope to publish articles covering such companies approximately 3 times per week, with extensive quarterly follow-ups and constant updates.I manage a concentrated portfolio targeted at avoiding losers and maximizing exposure to big winners. This means that often I'll rate great companies at a 'Hold' because their growth opportunity is below my threshold, or their d ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

TransMedics (TMDX) reported $143.82 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 32.2%. EPS of $0.66 for the same period compares to $0.12 a year ago.The reported revenue represents a surprise of -0.76% over the Zacks Consensus Estimate of $144.93 million. With the consensus EPS estimate being $0.37, the EPS surprise was +78.38%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wal ...

TransMedics (TMDX) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +78.38%. A quarter ago, it was expected that this medical technology company would post earnings of $0.48 per share when it actually produced earnings of $0.92, delivering a surprise of +91.67%.Over the last four quart ...

TransMedics Group (NasdaqGM:TMDX) Q3 2025 Earnings Call October 29, 2025 04:30 PM ET Speaker4Good afternoon and welcome to the TransMedics Group Inc. third quarter 2025 earnings conference call. At this time, all participants are in the listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. If you require operator assistance, please press star and then zero. I would now like to turn the call ove ...

TransMedics Q3 2025 Performance Highlights October 29, 2025 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements regarding future results and events, including financial guidance and projected estimates. Investors are cautioned not to place undue reliance on these forward-looking statements. For this purpose, all statements other than statements of historical facts contained in this presentation are forward-looking statements. The words "believe," "may," ...